EA200801863A1 - Новые соли присоединения ингибиторов ангиотензин-i-превращающего фермента с no-донорными кислотами, способ их получения и фармацевтическая композиция, которая их содержит - Google Patents

Новые соли присоединения ингибиторов ангиотензин-i-превращающего фермента с no-донорными кислотами, способ их получения и фармацевтическая композиция, которая их содержит

Info

Publication number
EA200801863A1
EA200801863A1 EA200801863A EA200801863A EA200801863A1 EA 200801863 A1 EA200801863 A1 EA 200801863A1 EA 200801863 A EA200801863 A EA 200801863A EA 200801863 A EA200801863 A EA 200801863A EA 200801863 A1 EA200801863 A1 EA 200801863A1
Authority
EA
Eurasian Patent Office
Prior art keywords
angiotensin
accession
turning
production
pharmaceutical composition
Prior art date
Application number
EA200801863A
Other languages
English (en)
Other versions
EA015092B1 (ru
Inventor
Гийом Де-Нантей
Бернар Портевен
Филипп Глоанек
Жан-Жилль Парментье
Ален Бенуа
Тони Вербёре
Ален Рупен
Кристин Курше
Серж Симоне
Original Assignee
Ле Лаборатуар Сервье
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39539691&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200801863(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ле Лаборатуар Сервье filed Critical Ле Лаборатуар Сервье
Publication of EA200801863A1 publication Critical patent/EA200801863A1/ru
Publication of EA015092B1 publication Critical patent/EA015092B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30Oxygen or sulfur atoms
    • C07D233/32One oxygen atom
    • C07D233/36One oxygen atom with hydrocarbon radicals, substituted by nitrogen atoms, attached to ring nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/081,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Соединения формулы (I), где А представляет собой соединение - ингибитор ангиотензин-превращающего фермента, содержащее по крайней мере одну солеобразующую основную функцию, В представляет собой соединение, содержащее по крайней мере одну солеобразующую кислотную функцию и по крайней мере одну NO донорную группу, m представляет собой количество кислотных функций В, которые были превращены в соль, и n представляет собой количество основных функций А, которые были превращены в соль, где связь или связи между А и В имеют ионную природу. Медикаменты.
EA200801863A 2007-09-21 2008-09-19 Соли присоединения ингибиторов ангиотензин-i-превращающего фермента с no-донорными кислотами, способ их получения и содержащая их фармацевтическая композиция EA015092B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0706629A FR2921365B1 (fr) 2007-09-21 2007-09-21 Nouveaux sels d'addition d'inhibiteurs d'enzyme de conversion de l'angiotensine a des acides donneurs de no, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (2)

Publication Number Publication Date
EA200801863A1 true EA200801863A1 (ru) 2009-04-28
EA015092B1 EA015092B1 (ru) 2011-06-30

Family

ID=39539691

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200801863A EA015092B1 (ru) 2007-09-21 2008-09-19 Соли присоединения ингибиторов ангиотензин-i-превращающего фермента с no-донорными кислотами, способ их получения и содержащая их фармацевтическая композиция

Country Status (43)

Country Link
US (1) US7981920B2 (ru)
EP (2) EP2236495A1 (ru)
JP (1) JP4903187B2 (ru)
KR (1) KR101070056B1 (ru)
CN (1) CN101391973A (ru)
AP (1) AP2010005204A0 (ru)
AR (1) AR068488A1 (ru)
AT (1) ATE476416T1 (ru)
AU (1) AU2008217013B8 (ru)
BR (1) BRPI0804073A2 (ru)
CA (1) CA2639700C (ru)
CL (1) CL2008002725A1 (ru)
CR (1) CR11320A (ru)
CY (1) CY1110782T1 (ru)
DE (1) DE602008002027D1 (ru)
DK (1) DK2039682T3 (ru)
EA (1) EA015092B1 (ru)
EC (1) ECSP10010040A (ru)
ES (1) ES2349493T3 (ru)
FR (1) FR2921365B1 (ru)
GE (1) GEP20125479B (ru)
HN (1) HN2010000533A (ru)
HR (1) HRP20100545T1 (ru)
JO (1) JO2664B1 (ru)
MA (1) MA30320B1 (ru)
MX (1) MX2008011954A (ru)
MY (1) MY144927A (ru)
NI (1) NI201000038A (ru)
NZ (1) NZ572988A (ru)
PA (1) PA8796701A1 (ru)
PE (1) PE20091190A1 (ru)
PL (1) PL2039682T3 (ru)
PT (1) PT2039682E (ru)
RS (1) RS51433B (ru)
SA (1) SA08290599B1 (ru)
SG (1) SG151200A1 (ru)
SI (1) SI2039682T1 (ru)
SV (1) SV2010003511A (ru)
TN (1) TN2010000111A1 (ru)
TW (1) TWI370118B (ru)
UY (1) UY31339A1 (ru)
WO (1) WO2009074733A2 (ru)
ZA (1) ZA200808062B (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2961105B1 (fr) 2010-06-15 2013-02-08 Servier Lab Utilisation de l'association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine pour le traitement de l'insuffisance cardiaque
US10314816B2 (en) 2012-06-08 2019-06-11 Wisconsin Alumni Research Foundation Antimicrobial compounds, compositions and methods of use thereof
CN103848795B (zh) * 2014-03-07 2016-08-17 山东大学 一种1,2,5-噁二唑-2-氧化物组蛋白去乙酰化酶抑制剂及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4218582A1 (de) * 1992-06-05 1993-12-09 Cassella Ag Pyridyl-1,2,5-oxadiazol-carbonamid-2-oxide
IT1295694B1 (it) * 1996-11-14 1999-05-27 Nicox Sa Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica
WO2000012110A2 (en) * 1998-08-26 2000-03-09 Queen's University At Kingston Use of anti(w)pressor agents for vascular remodeling in genital dysfunction
DE10033580A1 (de) 2000-04-10 2001-10-11 Bayer Ag Verfahren zur Herstellung von Ditaurin und seinen Salzen
AUPS236902A0 (en) * 2002-05-16 2002-06-13 Northern Sydney Area Health Service Composition and method for treating hypertension
WO2004050084A2 (en) * 2002-11-29 2004-06-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ace-inhibitors having antioxidant and nitricoxid-donor activity
US20070010571A1 (en) * 2003-08-20 2007-01-11 Nitromed, Inc. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
WO2006078995A1 (en) * 2005-01-21 2006-07-27 Nitromed, Inc. Cardiovascular compounds comprising heterocyclic nitric oxide donor group compositions and methods of use
JP2008533171A (ja) * 2005-03-18 2008-08-21 ニトロメッド インコーポレーティッド アンギオテンシン変換酵素阻害剤の有機酸化窒素増強塩、組成物および使用法
RU2271202C1 (ru) * 2005-05-04 2006-03-10 Михаил Владимирович Покровский Способ коррекции эндотелиальной дисфункции
WO2007016136A2 (en) * 2005-07-28 2007-02-08 Nitromed, Inc. Organic nitric oxide enhancing salts of cyclooxygenase-2 selective inhibitors, compositons and methods of use
US7838023B2 (en) * 2005-11-16 2010-11-23 Nitromed, Inc. Furoxan compounds, compositions and methods of use
DE602006017724D1 (de) * 2005-11-23 2010-12-02 Nicox Sa Salicylsäurederivate

Also Published As

Publication number Publication date
AR068488A1 (es) 2009-11-18
MY144927A (en) 2011-11-30
WO2009074733A2 (fr) 2009-06-18
CN101391973A (zh) 2009-03-25
TN2010000111A1 (fr) 2011-09-26
HN2010000533A (es) 2013-07-08
ATE476416T1 (de) 2010-08-15
DK2039682T3 (da) 2010-11-08
FR2921365A1 (fr) 2009-03-27
ZA200808062B (en) 2009-11-25
EP2039682B1 (fr) 2010-08-04
JO2664B1 (en) 2012-06-17
FR2921365B1 (fr) 2012-10-12
KR20090031298A (ko) 2009-03-25
AU2008217013A1 (en) 2009-04-09
WO2009074733A3 (fr) 2009-08-20
PT2039682E (pt) 2010-09-27
JP2009137935A (ja) 2009-06-25
JP4903187B2 (ja) 2012-03-28
US20090082393A1 (en) 2009-03-26
GEP20125479B (en) 2012-04-25
SG151200A1 (en) 2009-04-30
CR11320A (es) 2010-06-29
AU2008217013B8 (en) 2012-10-04
TWI370118B (en) 2012-08-11
US7981920B2 (en) 2011-07-19
HRP20100545T1 (hr) 2010-11-30
SA08290599B1 (ar) 2011-05-04
SV2010003511A (es) 2010-07-29
CY1110782T1 (el) 2015-06-10
TW200920352A (en) 2009-05-16
PE20091190A1 (es) 2009-08-09
DE602008002027D1 (de) 2010-09-16
ES2349493T3 (es) 2011-01-04
MA30320B1 (fr) 2009-04-01
CA2639700A1 (fr) 2009-03-21
PL2039682T3 (pl) 2010-10-29
EP2236495A1 (fr) 2010-10-06
ECSP10010040A (es) 2010-04-30
KR101070056B1 (ko) 2011-10-04
CL2008002725A1 (es) 2009-06-12
BRPI0804073A2 (pt) 2009-06-16
EA015092B1 (ru) 2011-06-30
NI201000038A (es) 2010-07-15
CA2639700C (fr) 2012-08-28
EP2039682A1 (fr) 2009-03-25
RS51433B (en) 2011-04-30
AU2008217013B2 (en) 2012-08-16
SI2039682T1 (sl) 2010-10-29
AP2010005204A0 (en) 2010-04-30
UY31339A1 (es) 2008-10-31
NZ572988A (en) 2010-07-30
PA8796701A1 (es) 2009-09-17
AU2008217013A8 (en) 2012-10-04
MX2008011954A (es) 2009-03-20

Similar Documents

Publication Publication Date Title
CY1125155T1 (el) Κρυσταλλικες μορφες αναστολεα προλυλο υδροξυλασης
EA201101026A1 (ru) Ингибиторы бета-секретазы
PE20131047A1 (es) Compuestos heterociclicos moduladores del acido urico
EA201390934A1 (ru) Композиции и способы модулирования fxr
EA201290416A1 (ru) Новые спиропиперидиновые соединения
EA201070572A1 (ru) Модуляция транспорта белков
EA200900812A1 (ru) Производные 4-имидазолил-1,2,3,4-тетрагидрохинолина и их применение в качестве ингибиторов альдостерон/11-бета-гидроксилазы
ATE425961T1 (de) Salze substituierter allophansaureester und deren verwendung in arzneimitteln
EA201200036A1 (ru) Способ лечения заболеваний
NI201100149A (es) Derivados de tiadiazoles y oxadiazoles, su preparación y su aplicación en terapia.
NZ601805A (en) Method for preparing tetrazole methanesulfonic acid salts, and novel compound used in same
EA200801777A1 (ru) α КРИСТАЛЛИЧЕСКАЯ ФОРМА АРГИНИНОВОЙ СОЛИ ПЕРИНДОПРИЛА, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, КОТОРЫЕ ЕЁ СОДЕРЖАТ
ATE495158T1 (de) Substituierte tetrahydroisochinoline als mmp- inhibitoren, verfahren zu ihrer herstellung und ihre verwendung als medikament
EA200801863A1 (ru) Новые соли присоединения ингибиторов ангиотензин-i-превращающего фермента с no-донорными кислотами, способ их получения и фармацевтическая композиция, которая их содержит
EA201390336A1 (ru) Способ получения промежуточного соединения для синтеза лекарственного средства
EA201170057A1 (ru) Способ получения замещенных 2-аминотиазолонов
BR112012017447A2 (pt) derivados de ácidos carboxílicos heterocíclicos tendo um anel oxazolopirimidina 2,5-substituído
EA200800464A1 (ru) Фармацевтическая композиция, содержащая периндоприл или его соли
DE502006009412D1 (de) Matrixkontrolliertes transdermales system mit salzen der ace-hemmer-dicarbonsäuren
ECSP12012207A (es) Procedimiento para la preparación de 2-(ciclohexilmetil)-n-{2-[(2s)-1-metilpirrolidin-2-il]etil}-1,2,3,4-tetrahidroisoquinolin-7-sulfonamida
EA201591487A1 (ru) Производные замещенной бисфенилбутановой кислоты в качестве ингибиторов nep с улучшенной in vivo эффективностью
NZ602703A (en) Arylfluorophosphate inhibitors of intestinal apical membrane sodium/phosphate co-transport
EA200701177A1 (ru) Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их
CU20100051A7 (es) Nuevas sales de adición de inhibidores de la enzima de conversión de angiotensina a ácidos donadores de no, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
EA201200849A1 (ru) Новые азабицикло[3.1.0]гекс-2-ильные соединения, способ их получения и фармацевтические композиции, содержащие их

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU